Marlies S Wijsenbeek

Sep 12, 2023 | jamanetwork.com | Toby Maher |Paul Ford |Galapagos NV |Marlies S Wijsenbeek

Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis—Reply Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis Toby M. Maher, MD, PhD; Paul Ford, MD, PhD; Kevin K. Brown, MD; Ulrich Costabel, MD, PhD; Vincent Cottin, MD, PhD; Sonye K. Danoff, MD, PhD; Irene Groenveld, MSc; Eric Helmer, PharmD; R. Gisli Jenkins, MD, PhD; Julie Milner, PhD; Geert Molenberghs, PhD; Bjorn Penninckx, MD; Matthew J.

Jun 1, 2023 | books.ersjournals.com | Peter M.A. Calverley |Thomas Wagner |Marc Humbert |Marlies S Wijsenbeek

Diagnosing rare diseases can be challenging, and treating these conditions is complex because of their often quite specific needs and treatment options. To address this, the European Respiratory Society (ERS) has published Rare Diseases of the Respiratory System.

May 4, 2023 | medscape.com | Jeffrey J Swigris |Marlies S Wijsenbeek

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jeffrey Swigris, DO: Welcome to Medscape InDiscussion on the topic of idiopathic pulmonary fibrosis, or IPF.

Mar 6, 2023 | healio.com | Isabella Hornick |Kristen Dowd |Marlies S Wijsenbeek

Source/Disclosures Disclosures: This study was funded by the Dutch Sarcoidosis Patient Association. Wijsenbeek reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures. The editorial authors report no relevant financial disclosures. Source/Disclosures Disclosures: This study was funded by the Dutch Sarcoidosis Patient Association.